CHM 2101
Alternative Names: Cadherin 17 chimeric antigen receptor-positive (CAR) T cells; Cadherin-17; CDH17-CAR T; CHM-2101; CHM-2101 CAR-T cellsLatest Information Update: 05 Jun 2024
At a glance
- Originator University of Pennsylvania
- Developer Chimeric Therapeutics; University of Pennsylvania
- Class Antineoplastics; Antineoplastons; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Colorectal cancer; Gastric cancer; Neuroendocrine tumours
- Preclinical Pancreatic cancer; Solid tumours
Most Recent Events
- 31 May 2024 Phase-I/II clinical trials in Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06055439)
- 31 May 2024 Phase-I/II clinical trials in Gastric cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06055439)
- 31 May 2024 Phase-I/II clinical trials in Neuroendocrine tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06055439)